The follicle-stimulating hormone receptor: A novel target in genitourinary malignancies

Urologic Oncology: Seminars and Original Investigations, 04/20/2012

The Follicle–stimulating hormone receptor (FSHR), which was previously believed to be expressed primarily in the ovary and testis, was recently found to be expressed in the tumor blood vessels of many solid tumor types, including prostate adenocarcinoma, urothelial carcinoma, and renal cell carcinoma. While the biologic significance of FSHR in tumor blood vessels has yet to be elucidated, FSHR may contribute to neoangiogenesis.

Print Article Summary Cat 2 CME Report